immunotherapy

Complete Genomics Announces Spatial Omics Distributor Agreement, Debuts Spatial Xcellerator Grant Program at SITC 2024

HOUSTON, Nov. 5, 2024 /PRNewswire/ -- At the Society for Immunotherapy of Cancer (SITC) Annual Meeting (Nov. 6-10, 2024), Complete…

1 year ago

LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH

MINNEAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the release of clinically relevant spatial biology data.…

1 year ago

Cantargia Presents Promising Preclinical Results on Nadunolimab With Antibody-Drug Conjugates at Major Immuno-Oncology Conference

LUND, SWEDEN / ACCESSWIRE / November 05, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported preclinical results…

1 year ago

OncoResponse to Present Phase 1 Results of Clinical Study of OR502, anti-LILRB2 Antibody, as a Late-Breaker Poster Presentation at SITC 2024

HOUSTON, Nov. 4, 2024 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer…

1 year ago

CureVac to Present at the 12th International mRNA Health Conference

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…

1 year ago

Renovaro Issues Shareholder Letter and Provides Corporate Update

LOS ANGELES, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered…

1 year ago

SHASQI TO PRESENT AT WORLD ADC AND SITC CONFERENCES

SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company using in-vivo click chemistry to enable pre-targeting…

1 year ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…

1 year ago

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit…

1 year ago

Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy in Advanced Colorectal Cancer

Trial builds upon promising evidence of clinical activity of TTX-080 when combined cetuximab, presented at ASCO 2024SOUTH SAN FRANCISCO, Calif.,…

1 year ago